Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Original Article
  • Published:

Antithrombotic therapy in hypertension: a Cochrane Systematic review

Journal of Human Hypertension volume 19, pages 185–196 (2005)Cite this article

Abstract

Although elevated systemic blood pressure (BP) results in high intravascular pressure, the main complications of hypertension are related to thrombosis rather than haemorrhage. It therefore seemed plausible that use of antithrombotic therapy may be useful in preventing thrombosis-related complications of elevated BP. The objectives were to conduct a systematic review of the role of antiplatelet therapy and anticoagulation in patients with BP, to address the following hypotheses: (i) antiplatelet agents reduce total deaths and/or major thrombotic events when compared to placebo or other active treatment; and (ii) oral anticoagulants reduce total deaths and/or major thromboembolic events when compared to placebo or other active treatment. A systematic review of randomised studies in patients with elevated BP was performed. Studies were included if they were >3 months in duration and compared antithrombotic therapy with control or other active treatment. One meta-analysis of antiplatelet therapy for secondary prevention in patients with elevated BP reported an absolute reduction in vascular events of 4.1% as compared to placebo. Acetylsalicylic acid (ASA) did not reduce stroke or ‘all cardiovascular events’ compared to placebo in primary prevention patients with elevated BP and no prior cardiovascular disease. Based on one large trial, ASA taken for 5 years reduced myocardial infarction (ARR, 0.5%, NNT 200 for 5 years), increased major haemorrhage (ARI, 0.7%, NNT 154), and did not reduce all cause mortality or cardiovascular mortality. In two small trials, warfarin alone or in combination with ASA did not reduce stroke or coronary events. Glycoprotein IIb/IIIa inhibitors as well as ticlopidine and clopidogrel have not been sufficiently evaluated in patients with elevated BP. To conclude for primary prevention in patients with elevated BP, antiplatelet therapy with ASA cannot be recommended since the magnitude of benefit, a reduction in myocardial infarction, is negated by a harm of similar magnitude, an increase in major haemorrhage. For secondary prevention in patients with elevated BP, antiplatelet therapy is recommended because the magnitude of the absolute benefit is many times greater. Warfarin therapy alone or in combination with aspirin in patients with elevated BP cannot be recommended because of lack of demonstrated benefit. Further trials of antithrombotic therapy are required in patients with elevated BP.

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

Figure 1

Similar content being viewed by others

References

  1. Collins R, MacMahon S . Blood pressure, antihypertensive drug treatment and the risks of stroke and of coronary heart disease. Br Med Bull 1994; 50: 272–298.

    Article  CAS  PubMed  Google Scholar 

  2. Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 2, Short-term reductions in blood pressure: overview of randomised drug trials in their epidemiological context. Lancet 1990; 335: 827–838.

    Article  CAS  PubMed  Google Scholar 

  3. Collins R et al. Blood pressure, stroke, and coronary heart disease. Part 1, Prolonged differences in blood pressure: prospective observational studies corrected for the regression dilution bias. Lancet 1990; 335: 765–774.

    Article  PubMed  Google Scholar 

  4. Prospective Studies Collaboration. Age-specific relevance of usual blood pressure to vascular mortality: a meta-analysis of individual data for one million adults in 61 prospective studies. Lancet 2002; 360: 1903–1913.

  5. Lip GYH, Edmunds E, Beevers DG . Should patients with hypertension receive antithrombotic therapy? J Intern Med 2001; 249: 205–214.

    Article  CAS  PubMed  Google Scholar 

  6. Lip GYH, Beevers DG . Abnormalities of rheology and coagulation in hypertension. J Hum Hypertens 1994; 8: 693–702.

    CAS  PubMed  Google Scholar 

  7. Lee AJ . The role of rheological and haemostatic factors in hypertension. J Hum Hypertens 1997; 11: 767–776.

    Article  CAS  PubMed  Google Scholar 

  8. Vanhoutte PM . Endothelial dysfunction in hypertension. J Hypertens Suppl 1996; 14: S83–S93.

    Article  CAS  PubMed  Google Scholar 

  9. Lip GY, Blann AD . Does hypertension confer a prothrombotic state? Virchow's triad revisited. Circulation 2000; 101: 218–220.

    Article  CAS  PubMed  Google Scholar 

  10. Lip GYH et al. Relationship of endothelium, thrombogenesis, and haemorrheology in systemic hypertension to ethnicity and left ventricular hypertrophy. Am J Cardiol 1997; 80: 1566–1571.

    Article  CAS  PubMed  Google Scholar 

  11. Segal JB et al. Anticoagulants or antiplatelet therapy for non-rheumatic atrial fibrillation and flutter (Cochrane Review). In: Cochrane Library, Issue 2. Update Software: Oxford, 2001 CD001938.

    Google Scholar 

  12. SPAF II Study. Warfarin versus aspirin for prevention of thromboembolism in atrial fibrillation: Stroke Prevention in Atrial Fibrillation II Study. Lancet 1994; 343: 687–691.

  13. Lip GYH, Gibbs CR . Antiplatelet agents versus control or anticoagulation for heart failure in sinus rhythm (Cochrane Review). In: The Cochrane Library, Issue 4. John Wiley & Sons, Ltd: Chichester, UK, 2001 CD003333.

    Google Scholar 

  14. WHO–ISHGMH. World Health Organization–International Society of Hypertension Guidelines for the management of hypertension. Guidelines Subcommittee. J Hypertens 1999; 17: 151–183.

  15. Ramsay L et al. Guidelines for management of hypertension: report of the third working party of the British Hypertension Society. J Hum Hypertens 1999; 13: 569–592.

    Article  CAS  PubMed  Google Scholar 

  16. WHO Guidelines Sub-Committee. Guidelines for the management of mild hypertension: memorandum from a World Health Organization/International Society of Hypertension meeting. J Hypertens 1993; 11: 905–918.

  17. Clarke M, Oxman AD (eds). Cochrane Reviewers' Handbook 4.2.0 [updated March 2003]. In: The Cochrane Library, Issue 2, 2003. Oxford: Update Software.

    Google Scholar 

  18. Mulrow CD, Cook DJ, Davidoff F . Systematic reviews: critical links in the great chain of evidence. Ann Intern Med 1997; 126: 389–391.

    Article  CAS  PubMed  Google Scholar 

  19. Meade TW, Brennan PJ . Determination of who may derive most benefit from aspirin in primary prevention: subgroup results from a randomised controlled trial. BMJ 2000; 321: 13–17.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. The Medical Research Council's General Practice Research Framework. Thrombosis prevention trial: randomised trial of low-intensity oral anticoagulation with warfarin and low-dose aspirin in the primary prevention of ischaemic heart disease in men at increased risk. Lancet 1998; 351: 233–241.

  21. O'Connor CM et al. Comparison of two aspirin doses on ischemic stroke in post-myocardial infarction patients in the warfarin (Coumadin) Aspirin Reinfarction Study (CARS). Am J Cardiol 2001; 88: 541–546.

    Article  CAS  PubMed  Google Scholar 

  22. Mohr JP et al. A comparison of warfarin and aspirin for the prevention of recurrent ischemic stroke. N Engl J Med 2001; 345: 1444–1451.

    Article  CAS  PubMed  Google Scholar 

  23. The Stroke Prevention in Reversible Ischemia Trial (SPIRIT) Study Group. A randomized trial of anticoagulants versus aspirin after cerebral ischemia of presumed arterial origin. Ann Neurol 1997; 42: 857–865.

  24. Huynh T et al. Aspirin, warfarin or the combination for secondary prevention of coronary events in patients with acute coronary syndromes and prior coronary artery bypass surgery. Circulation 2001; 103: 3069–3074.

    Article  CAS  PubMed  Google Scholar 

  25. Schuhlen H et al. Incidence of thrombotic occlusion and major adverse cardiac events between two and four weeks after coronary stent placement: analysis of 5,678 patients with a four-week ticlopidine regimen. J Am Coll Cardiol 2001; 37: 2066–2073.

    Article  CAS  PubMed  Google Scholar 

  26. Thel MC et al. Clinical risk factors for ischemic complications after percutaneous coronary interventions: results from the EPIC trial. The EPIC Investigators. Am Heart J 1999; 137: 264–273.

    Article  CAS  PubMed  Google Scholar 

  27. Kleiman NS et al. Diabetes mellitus, glycoprotein IIb/IIIa blockade, and heparin: evidence for a complex interaction in a multicenter trial. EPILOG Investigators. Circulation 1998; 97: 1912–1920.

    Article  CAS  PubMed  Google Scholar 

  28. Novo S et al. Effects of captopril and ticlopidine, alone or in combination, in hypertensive patients with intermittent claudication. Int Angiol 1996; 15: 169–174.

    CAS  PubMed  Google Scholar 

  29. Finelli C et al. Ticlopidine lowers plasma fibrinogen in patients with polycythaemia rubra vera and additional thrombotic risk factors. A double-blind controlled study. Acta Haematol 1991; 85: 113–118.

    Article  CAS  PubMed  Google Scholar 

  30. Hass WK, et al., for the Ticlopidine Aspirin Stroke Study Group. A randomised trial comparing ticlopidine hydrochloride with aspirin for the prevention of stroke in high-risk patients. N Engl J Med 1989; 321: 501–507.

    Article  CAS  PubMed  Google Scholar 

  31. Hansson L, et al., for the HOT Study Group. Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principle results of the Hypertension Optimal Treatment randomised trial. Lancet 1998; 351: 1755–1762.

    Article  CAS  PubMed  Google Scholar 

  32. CAPRIE Steering Committee. A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). Lancet 1996; 348: 1329–1339.

  33. Antiplatelet Trialists' Collaboration. Collaborative overview of randomised trials of antiplatelet therapy—I: Prevention of death, myocardial infarction, and stroke by prolonged antiplatelet therapy in various categories of patients. Antiplatelet Trialists' Collaboration. BMJ 1994; 308: 81–106.

  34. O'Neill WW et al. Long-term treatment with a platelet glycoprotein-receptor antagonist after percutaneous coronary revascularization. EXCITE Trial Investigators. Evaluation of oral xemilofiban in controlling thrombotic events. N Engl J Med 2000; 342: 1316–1324.

    Article  CAS  PubMed  Google Scholar 

  35. Dickersin K, Herxheimer A . Introduction: the quality of the medical evidence: is it good enough? Int J Technol Assess Health Care 1996; 12: 187–189.

    Article  CAS  PubMed  Google Scholar 

  36. Lefebvre C, McDonald S . Development of a sensitive search strategy for reports of randomized controlled trials in EMBASE. Paper presented at the Fourth International Cochrane Colloquium, Adelaide, Australia, 20–24 October 1996.

  37. Ajani UA et al. Alcohol consumption and risk of coronary heart disease by diabetes status. Circulation 2000; 102: 500–505.

    Article  CAS  PubMed  Google Scholar 

  38. Bhatt DL et al. Reduction in the need for hospitalization for recurrent ischemic events and bleeding with clopidogrel instead of aspirin. CAPRIE investigators. Am Heart J 2000; 140: 67–73.

    Article  CAS  PubMed  Google Scholar 

  39. Bhatt DL et al. Superiority of clopidogrel versus aspirin in patients with prior cardiac surgery. Circulation 2001; 103: 363–368.

    Article  CAS  PubMed  Google Scholar 

  40. Califf RM et al. Prediction of 1-year survival after thrombolysis for acute myocardial infarction in the global utilization of streptokinase and TPA for occluded coronary arteries trial. Circulation 2000; 101: 2231–2238.

    Article  CAS  PubMed  Google Scholar 

  41. Caravaca F et al. Haemodynamic changes induced by the correction of anaemia by erythropoietin: role of antiplatelet therapy. Nephrol Dial Transplant 1995; 10: 1720–1724.

    CAS  PubMed  Google Scholar 

  42. Cook ME et al. Comparative effects of nabumetone, sulindac, and ibuprofen on renal function. J Rheumatol 1997; 24: 1137–1144.

    CAS  PubMed  Google Scholar 

  43. Cusson JR et al. Effect of ketoprofen on blood pressure, endocrine and renal responses to chronic dosing with captopril in patients with essential hypertension. Blood Press 1992; 1: 162–167.

    Article  CAS  PubMed  Google Scholar 

  44. Drapkin A, Merskey C . Anticoagulant therapy after acute myocardial infarction. Relation of therapeutic benefit to patient's age, sex, and severity of infarction. JAMA 1972; 222: 541–548.

    Article  CAS  PubMed  Google Scholar 

  45. Forbes CD, for the ESPS Investigators. Secondary stroke prevention with low-dose aspirin, sustained release dipyridamol alone and in combination. Thromb Res 1998; 92: S1–S6.

    Article  CAS  PubMed  Google Scholar 

  46. Ferri C et al. Enhanced blood pressure response to cyclooxygenase inhibition in salt-sensitive human essential hypertension. Hypertension 1993; 21(6 Part 1): 875–881.

    Article  CAS  PubMed  Google Scholar 

  47. Fisher LD, Gent M, Buller HR . Active-control trials: how would a new agent compare with placebo? A method illustrated with clopidogrel, aspirin, and placebo. Am Heart J 2001; 141: 26–32.

    Article  CAS  PubMed  Google Scholar 

  48. Forbes CD et al. Clopidogrel compatibility with concomitant cardiac co-medications: a study of its interactions with a beta-blocker and a calcium uptake antagonist. Semin Thromb Hemost 1999; 25: 55–60.

    CAS  PubMed  Google Scholar 

  49. Furey SA, Vargas R, McMahon FG . Renovascular effects of nonprescription ibuprofen in elderly hypertensive patients with mild renal impairment. Pharmacotherapy 1993; 13: 143–148.

    CAS  PubMed  Google Scholar 

  50. Gurwitz JH et al. The impact of ibuprofen on the efficacy of antihypertensive treatment with hydrochlorothiazide in elderly persons. J Gerontol A Biol Sci Med Sci 1996; 51: M74–M79.

    Article  CAS  PubMed  Google Scholar 

  51. Harker LA, Boissel JP, Pilgrim AJ, Gent M . Comparative safety and tolerability of clopidogrel and aspirin: results from CAPRIE. CAPRIE Steering Committee and Investigators. Clopidogrel versus aspirin in patients at risk of ischaemic events. Drug Saf 1999; 21: 325–335.

    Article  CAS  PubMed  Google Scholar 

  52. Harpaz D et al. Effect of aspirin on the mortality in women with symptomatic or silent myocardial infarction. Am J Cardiol 1996; 78: 1215–1219.

    Article  CAS  PubMed  Google Scholar 

  53. Hartmann D et al. Study on the possible interaction between tenoxicam and atenolol in hypertensive patients. Arzneimittelforschung 1995; 45: 494–498.

    CAS  PubMed  Google Scholar 

  54. Harvey PJ et al. Effect of indomethacin on blood pressure control during treatment with nitrendipine. Blood Press 1995; 4: 307–312.

    Article  CAS  PubMed  Google Scholar 

  55. Hermida RC et al. Influence of aspirin usage on blood pressure: dose and administration-time dependencies. Chronobiol Int 1997; 14: 619–637.

    Article  CAS  PubMed  Google Scholar 

  56. Herskovits E et al. Preventive treatment of cerebral transient ischemia: comparative randomized trial of pentoxifylline versus conventional antiaggregants. Eur Neurol 1985; 24: 73–81.

    Article  CAS  PubMed  Google Scholar 

  57. Hess H, Mietaschk A, Deichsel G . Drug-induced inhibition of platelet function delays progression of peripheral occlusive arterial disease. A prospective double-blind arteriographically controlled trial. Lancet 1985; 1: 415–419.

    Article  CAS  PubMed  Google Scholar 

  58. Houston MC et al. The effects of nonsteroidal anti-inflammatory drugs on blood pressures of patients with hypertension controlled by verapamil. Arch Intern Med 1995; 155: 1049–1054.

    Article  CAS  PubMed  Google Scholar 

  59. Houtsmuller AJ et al. The influence of teiclopidine on the natural course of retinal vein occlusion. Agents Actions Suppl 1984; 15: 219–229.

    CAS  PubMed  Google Scholar 

  60. Johnson AG et al. Potential mechanisms by which nonsteroidal anti-inflammatory drugs elevate blood pressure: the role of endothelin-1. J Hum Hypertens 1996; 10: 257–261.

    CAS  PubMed  Google Scholar 

  61. Klassen D et al. Assessment of blood pressure during treatment with naproxen or ibuprofen in hypertensive patients treated with hydrochlorothiazide. J Clin Pharmacol 1993; 33: 971–978.

    Article  CAS  PubMed  Google Scholar 

  62. Klassen DK, Jane LH, Young DY, Peterson CA . Assessment of blood pressure during naproxen therapy in hypertensive patients treated with nicardipine. Am J Hypertens 1995; 8: 146–153.

    Article  CAS  PubMed  Google Scholar 

  63. Lee IM et al. Exercise and risk of stroke in male physicians. Stroke 1999; 30: 1–6.

    Article  CAS  PubMed  Google Scholar 

  64. Lemak NA, Fields WS, Gary Jr HE . Controlled trial of aspirin in cerebral ischemia: an addendum. Neurology 1986; 36: 705–710.

    Article  CAS  PubMed  Google Scholar 

  65. Magagna A et al. Indomethacin raises blood pressure in untreated essential hypertensives: a double-blind randomly allocated study versus placebo. J Hypertens Suppl 1991; 9: S242–S243.

    CAS  PubMed  Google Scholar 

  66. Magagna A et al. Hemodynamic and humoral effects of low-dose aspirin in treated and untreated essential hypertensive patients. Blood Press 1994; 3: 236–241.

    Article  CAS  PubMed  Google Scholar 

  67. Maggioni AP et al. The risk of stroke in patients with acute myocardial infarction after thrombolytic and antithrombotic treatment. Gruppo Italiano per lo Studio della Sopravvivenza nell'Infarto Miocardico II (GISSI-2), and The International Study Group. N Engl J Med 1992; 327: 1–6.

    Article  CAS  PubMed  Google Scholar 

  68. Mehta SR et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001; 358: 527–533.

    Article  CAS  PubMed  Google Scholar 

  69. Mills EH, Whitworth JA, Andrews J, Kincaid-Smith P . Non-steroidal anti-inflammatory drugs and blood pressure. Aust N Z J Med 1982; 12: 478–482.

    Article  CAS  PubMed  Google Scholar 

  70. Minuz P, Barrow SE, Cockcroft JR, Ritter JM . Effects of non-steroidal anti-inflammatory drugs on prostacyclin and thromboxane biosynthesis in patients with mild essential hypertension. Br J Clin Pharmacol 1990; 30: 519–526.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  71. Minuz P et al. Amlodipine and haemodynamic effects of cyclo-oxygenase inhibition. Br J Clin Pharmacol 1995; 39: 45–50.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  72. Morgan T, Anderson A . Interaction of indomethacin with felodipine and enalapril. J Hypertens Suppl 1993; 11(Suppl 5): S338–S339.

    CAS  PubMed  Google Scholar 

  73. Morgan TO, Anderson A, Bertram D . Effect of indomethacin on blood pressure in elderly people with essential hypertension well controlled on amlodipine or enalapril. Am J Hypertens 2000; 13: 1161–1167.

    Article  CAS  PubMed  Google Scholar 

  74. Nawarskas JJ, Townsend RR, Cirigliano MD, Spinler SA . Effect of aspirin on blood pressure in hypertensive patients taking enalapril or losartan. Am J Hypertens 1999; 12(8 Part 1): 784–789.

    Article  CAS  PubMed  Google Scholar 

  75. Oosterga M et al. Effects of aspirin on angiotensin-converting enzyme inhibition and left ventricular dilation one year after acute myocardial infarction. Am J Cardiol 1998; 81: 1178–1181.

    Article  CAS  PubMed  Google Scholar 

  76. Pancera P et al. Changes in peripheral hemodynamics and vasodilating prostaglandins after high-dose short-term ibuprofen in chronically treated hypertensive patients. Prostaglandins Leukot Essent Fatty Acids 1996; 54: 217–222.

    Article  CAS  PubMed  Google Scholar 

  77. Peto R et al. Randomised trial of prophylactic daily aspirin in British male doctors. BMJ 1988; 296: 313–316.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  78. Steering Committee of the Physicians' Health Study Research Group. Final report on the aspirin component of the ongoing Physicians' Health Study. N Engl J Med 1989; 321: 129–135.

  79. Polonia J et al. Influence of non-steroidal anti-inflammatory drugs on renal function and 24 h ambulatory blood pressure-reducing effects of enalapril and nifedipine gastrointestinal therapeutic system in hypertensive patients. J Hypertens 1995; 13: 925–931.

    Article  CAS  PubMed  Google Scholar 

  80. Polonia J, Gama G, Santos A . [Reduction of the antihypertensive effects of enalapril by indomethacin. Its independence from renal sodium retention]. Rev Port Cardiol 1996; 15: 460, 485–492.

    Google Scholar 

  81. Collaborative Group of the Primary Prevention Project. Low-dose aspirin and vitamin E in people at cardiovascular risk: a randomised trial in general practice. Lancet 2001; 357: 89–95.

  82. Pritchard G et al. Do trandolapril and indomethacin influence renal function and renal functional reserve in hypertensive patients? Br J Clin Pharmacol 1997; 44: 145–149.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  83. Proudman SM et al. Treatment of poor-prognosis early rheumatoid arthritis. A randomized study of treatment with methotrexate, cyclosporin A, and intra-articular corticosteroids compared with sulfasalazine alone. Arthritis Rheum 2000; 43: 1809–1819.

    Article  CAS  PubMed  Google Scholar 

  84. Puranen J, Laakso M, Riekkinen Sr PJ, Sivenius J . Efficacy of antiplatelet treatment in hypertensive patients with TIA or stroke. J Cardiovasc Pharmacol 1998; 32: 291–294.

    Article  CAS  PubMed  Google Scholar 

  85. Mahaffey KW et al. Stroke in patients with acute coronary syndromes: incidence and outcomes in the platelet glycoprotein IIb/IIIa in unstable angina. Receptor suppression using integrilin therapy (PURSUIT) trial. The PURSUIT Investigators. Circulation 1999; 99: 2371–2377.

    Article  CAS  PubMed  Google Scholar 

  86. Saloheimo P, Juvela S, Hillbom M . Use of aspirin, epistaxis and untreated hypertension as risk factors for primary intracerebral hemorrhage in middle-aged and elderly people. Stroke 2001; 32: 399–404.

    Article  CAS  PubMed  Google Scholar 

  87. Schreiber TL et al. Randomized trial of thrombolysis versus heparin in unstable angina. Circulation 1992; 86: 1407–1414.

    Article  CAS  PubMed  Google Scholar 

  88. Sivenius J et al. Antiplatelet therapy is effective in primary prevention of myocardial infarction in patients with a previous cerebrovascular ischemic event. Arch Neurol 1993; 50: 710–713.

    Article  CAS  PubMed  Google Scholar 

  89. Smith SR, Coffman TM, Svetkey LP . Effect of low-dose aspirin on thromboxane production and the antihypertensive effect of captopril. J Am Soc Nephrol 1993; 4: 1133–1139.

    CAS  PubMed  Google Scholar 

  90. Sturrock ND, Lang CC, Struthers AD . Indomethacin and cyclosporin together produce marked renal vasoconstriction in humans. J Hypertens 1994; 12: 919–924.

    Article  CAS  PubMed  Google Scholar 

  91. Takeuchi K et al. No adverse effect of non-steroidal anti-inflammatory drugs, sulindac and diclofenac sodium, on blood pressure control with a calcium antagonist, nifedipine, in elderly hypertensive patients. Tohoku J Exp Med 1991; 165: 201–208.

    Article  CAS  PubMed  Google Scholar 

  92. Thakur V, Cook ME, Wallin JD . Antihypertensive effect of the combination of fosinopril and HCTZ is resistant to interference by nonsteroidal anti-inflammatory drugs. Am J Hypertens 1999; 12(9 Part 1): 925–928.

    Article  CAS  PubMed  Google Scholar 

  93. Tison P et al. Treatment of hypertension with dihydropyridine calcium antagonists and aspirin. Blood Press Suppl 1994; 1: 57–60.

    CAS  PubMed  Google Scholar 

  94. Tsuji T, Yasu T, Katayama Y, Imanishi M . Different patterns of renal prostaglandins I2 and E2 in patients with essential hypertension with low to normal or high renin activity. J Hypertens 2000; 18: 1091–1096.

    Article  CAS  PubMed  Google Scholar 

  95. UK-TIA Study Group. The United Kingdom transient ischaemic attack (UK-TIA) aspirin trial: final results. J Neurol Neurosurg Psychiatry 1991; 54: 1044–1054.

  96. Walter E, Kaufmann W, Oster P . Does chronic aspirin treatment increase blood pressure in man? Klin Wochenschr 1981; 59: 297–299.

    Article  CAS  PubMed  Google Scholar 

  97. Whelton A et al. Cyclooxygenase-2—specific inhibitors and cardiorenal function: a randomized, controlled trial of celecoxib and rofecoxib in older hypertensive osteoarthritis patients. Am J Ther 2001; 8: 85–95.

    Article  CAS  PubMed  Google Scholar 

  98. Celis H et al. Interaction between nonsteroidal anti-inflammatory drug intake and calcium-channel blocker-based antihypertensive treatment in the Syst-Eur trial. J Hum Hypertens 2001; 15: 613–618.

    Article  CAS  PubMed  Google Scholar 

Download references

Acknowledgements

We acknowledge the support of the Sandwell & West Birmingham Hospitals NHS Trust Research and Development Program for the Haemostasis, Thrombosis and Vascular Biology Unit. We thank our colleagues in the Cochrane Hypertension Group for helpful comments and advice, as well as assisting with the detailed Cochrane peer review process.

Author information

Authors and Affiliations

  1. Haemostasis, Thrombosis, and Vascular Biology Unit, University Department of Medicine, City Hospital, Birmingham, UK

    D C Felmeden & G Y H Lip

Authors
  1. D C Felmeden
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G Y H Lip
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to G Y H Lip.

Additional information

Duality of interest

Our unit undertakes clinical trials of antithrombotic therapy in cardiovascular disease and stroke, and has received research funding from various pharmaceutical companies involved in thrombosis and antithrombotic therapy.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Felmeden, D., Lip, G. Antithrombotic therapy in hypertension: a Cochrane Systematic review. J Hum Hypertens 19, 185–196 (2005). https://doi.org/10.1038/sj.jhh.1001807

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.jhh.1001807

Keywords

This article is cited by

Search

Advanced search

Quick links